Top Mesothelioma Centers in Virginia

The best mesothelioma cancer centers in Virginia include university hospitals and research institutes where cancer specialists investigate promising treatments for pleural and peritoneal mesothelioma. Two Virginia cancer centers rank highly on U.S. News & World Report’s Best Hospitals and Best Regional Hospitals lists: The University of Virginia Medical Center in Charlottesville and the VCU Massey Comprehensive Cancer Center in Richmond. These regional hospitals offer excellent options for mesothelioma treatment in Virginia, including robotic surgery, CAR T-cell immunotherapy and heated intraperitoneal chemotherapy.

The Massey Cancer Center has had National Cancer Institute recognition for more than 50 years. As NCI-Designated Comprehensive Cancer Centers, both VCU Massey and the University of Virginia Medical Center meet the highest standards for treatment innovation, multidisciplinary patient care, support programs and clinical trials.

Locations of Virginia’s Top Cancer Centers

Mesothelioma patients in Virginia can find excellent treatment, cancer care and support services in Richmond, Charlottesville, Fairfax, Alexandria and other cities. The state’s only NCI-Designated cancer centers are VCU Massey in Richmond and the University of Virginia Medical Center in Charlottesville. Virginia Cancer Specialists locations in Central, Northern and Eastern Virginia provide medical oncology services to cancer patients throughout the state.

All Centers (3)

Top Doctors in Virginia

The top mesothelioma doctors in Virginia are mesothelioma specialists, not just general oncologists. Dr. Sandeep Khandhar is one of Virginia’s best pleural mesothelioma doctors, with more than 20 years of experience as a thoracic surgeon. Dr. Khandhar performs minimally invasive thoracic procedures for lung cancer and mesothelioma.

Pleural and peritoneal mesothelioma cases are complex, and having experts in immunotherapy, HIPEC, precision radiation therapy and targeted cancer treatments can make a significant difference in the quality of care. To provide the best mesothelioma treatment in Virginia, leading cancer doctors like Dr. Alex Spira in Fairfax are part of multidisciplinary care teams that create personalized treatment plans to support each stage of the patient’s diagnosis, including recovery and survivorship.

Dr. Sandeep Khandhar

Sandeep Khandhar

Pleural Specialist | Thoracic surgery

Expertise:
Minimally Invasive Surgery Vascular Surgery
Virginia Cancer Specialists • Fairfax, Virginia
View Profile
Expertise:
Minimally Invasive Surgery Vascular Surgery
Virginia Cancer Specialists
Fairfax, Virginia
View Profile

Dr. Sandeep J. Khandhar is a cardiothoracic surgeon in Fairfax who specializes in treating lung cancers with minimally invasive techniques. He is part of the Virginia Cancer Specialists group.

Read Bio
Dr. Alex Spira

Alex Spira

Pleural Specialist | Medical Oncology

Expertise:
Research Immunotherapy
Virginia Cancer Specialists • Fairfax, Virginia
View Profile
Expertise:
Research Immunotherapy
Virginia Cancer Specialists
Fairfax, Virginia
View Profile

Dr. Alex Spira is a medical oncologist with Virginia Cancer Specialists in Fairfax who sees patients with pleural mesothelioma.

Read Bio
Find a Specialist in Virginia
Searching…

Clinical Trials in Virginia

Clinical trials at NCI-Designated mesothelioma cancer centers in Virginia can provide access to groundbreaking mesothelioma treatment. Clinical research in the state has advanced ultrasound therapy, gene therapy and chemotherapy techniques for peritoneal and pleural mesothelioma treatments.

Participating in open clinical trials may offer access to the latest medical breakthroughs or cancer therapies. To find mesothelioma clinical trials in Virginia, speak with your doctor or one of our Patient Advocates.

NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Locations

  • California (1)

    • Stanford University — Palo Alto

  • Colorado (1)

    • Grand Valley Oncology — Grand Junction

  • Florida (1)

    • Sylvester Comprehensive Cancer Center — Miami

  • Illinois (3)

    • University Chicago Medicine — Chicago
    • Carle Cancer Center — Urbana
    • Midwestern Regional Medical Center, City of Hope Chicago — Zion

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (1)

    • Henry Ford Cancer Center — Detroit

  • New York (1)

    • New York University Langone Health — New York

  • Tennessee (1)

    • Sarah Cannon Tennessee Oncology — Nashville

  • Texas (1)

    • The University of Texas MD Anderson Cancer Center — Houston

  • Utah (1)

    • Huntsman Cancer Institute, University of Utah — Salt Lake City

  • Virginia (1)

    • Next Oncology Virginia — Fairfax

NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.

Locations

  • Georgia (1)

    • Winship Cancer Institute of Emory University — Atlanta

  • Illinois (1)

    • University of Chicago Medical Center — Chicago

  • Massachusetts (1)

    • Massachusetts General Hospital — Boston

  • Pennsylvania (1)

    • Abramson Cancer Center of the University of Pennsylvania — Philadelphia

  • Virginia (1)

    • University of Virginia Health System — Charlottesville

  • Washington (2)

    • Swedish Cancer Institute — Seattle
    • Fred Hutchinson Cancer Center — Seattle

NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Locations

  • California (2)

    • University of Southern California — Los Angeles
    • University of California, San Francisco — San Francisco

  • Colorado (1)

    • University of Colorado School of Medicine — Aurora

  • Illinois (1)

    • University of Chicago — Chicago

  • North Carolina (1)

    • University of North Carolina — Chapel Hill

  • Oklahoma (1)

    • University of Oklahoma — Oklahoma City

  • Texas (1)

    • MD Anderson Cancer Center — Houston

  • Virginia (1)

    • University of Virginia — Charlottesville

  • Washington (1)

    • Fred Hutchinson Cancer Center — Seattle

NCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Locations

  • California (1)

    • UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco

  • Illinois (1)

    • University of Chicago Medical Center — Chicago

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana-Farber Cancer Institute — Boston

  • Minnesota (1)

    • M Health Fairview University of Minnesota Medical Center — Minneapolis

  • New York (1)

    • Memorial Sloan Kettering Cancer Center — New York

  • Texas (2)

    • MD Anderson Cancer Center — Houston
    • NEXT Oncology — San Antonio

  • Virginia (1)

    • Virginia Cancer Specialists, PC — Arlington

NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Locations

  • Arizona (1)

    • Mayo Clinic Arizona — Phoenix

  • California (1)

    • Providence Medical Foundation — Santa Rosa

  • District of Columbia (1)

    • Johns Hopkins Sibley Memorial Hospital — Washington D.C.

  • Florida (4)

    • BRCR Global-Coral Springs — Coral Springs
    • Mayo Clinic Florida — Jacksonville
    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando
    • Moffitt Cancer Center — Tampa

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • Nebraska (1)

    • Nebraska Cancer Specialists — Omaha

  • New Jersey (1)

    • START Astera, LLC — East Brunswick

  • New York (1)

    • Columbia University Irving Medical Center — New York

  • Pennsylvania (1)

    • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University — Philadelphia

  • Tennessee (1)

    • Sarah Cannon Research Institute — Nashville

  • Texas (4)

    • START Dallas Fort Worth — Fort Worth
    • MD Anderson — Houston
    • NEXT Oncology Houston — Houston
    • NEXT Oncology Dallas — Irving

  • Utah (1)

    • START Mountain Region, LLC — West Valley City

  • Virginia (1)

    • NEXT Oncology Virginia — Fairfax

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Locations

  • Arizona (1)

    • Mayo Clinic — Phoenix

  • Colorado (1)

    • Rocky Mountain Cancer Centers, LLP – Oncology — Lone Tree

  • Florida (2)

    • Mayo Clinic — Jacksonville
    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando

  • Massachusetts (1)

    • Dana-Farber Cancer Institute — Brookline

  • Michigan (2)

    • The Cancer & Hematology Centers — Grand Rapids
    • Cancer and Hematology Centers of Western Michigan — Norton Shores

  • Minnesota (1)

    • Mayo Clinic — Rochester

  • New Jersey (1)

    • Rutgers Cancer Institute of New Jersey — New Brunswick

  • New York (4)

    • Perlmutter Cancer Center at NYU Langone Hospital Long Island — Mineola
    • David H Koch, Memorial Sloan Kettering Cancer Center — New York
    • New york cancer and blood specialists – Oncology — Port Jefferson Station
    • New york cancer and blood specialists – Oncology — Port Jefferson Station

  • North Carolina (2)

    • University of North Carolina – Gastroenterology and Hepatology — Chapel Hill
    • University of North Carolina — Chapel Hill

  • Tennessee (1)

    • Vanderbilt – Ingram Cancer Center — Nashville

  • Texas (5)

    • Ut Southwestern — Dallas
    • Texas Oncology – DFW — Fort Worth
    • MDACC — Houston
    • South Texas Accelerated Research Therapeutics — San Antonio
    • Texas Oncology, P.A. – Oncology — Tyler

  • Virginia (1)

    • Virginia Cancer Specialists, PC — Fairfax

NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Locations

  • Arizona (2)

    • USOR HonorHealth — Phoenix
    • USOR Arizona Oncology Associates — Tucson

  • California (4)

    • University of California Los Angeles Medical Center — Los Angeles
    • University of California, San Diego; Moores Cancer Center — San Diego
    • USOR Sansum Clinic — Santa Barbara
    • Providence Medical Foundation — Santa Rosa

  • Florida (3)

    • USOR Florida Cancer Specialists South — Fort Myers
    • USOR Florida Cancer Specialists North — St. Petersburg
    • USOR Florida Cancer Specialists East — West Palm Beach

  • Georgia (1)

    • Augusta University Georgia Cancer Center — Augusta

  • Kansas (1)

    • University of Kansas Medical Center (KUMC) — Westwood

  • Maryland (1)

    • USOR Maryland Oncology Hematology — Rockville

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (2)

    • Karmanos Cancer Institute — Detroit
    • START Midwest — Grand Rapids

  • Minnesota (1)

    • USOR Minnesota Oncology Hematology — Maplewood

  • New Jersey (1)

    • MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden

  • Ohio (1)

    • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus

  • Oklahoma (1)

    • University of Oklahoma – Health Sciences Center — Oklahoma City

  • Oregon (2)

    • USOR Oncology Associates of Oregon, P.C. — Eugene
    • Compass Oncology – Rose Quarter — Portland

  • Pennsylvania (2)

    • USOR Alliance Cancer Specialist — Doylestown
    • Allegheny Health Network — Pittsburgh

  • Rhode Island (1)

    • Women and Infants Hospital of Rhode Island — Providence

  • Tennessee (2)

    • Sarah Cannon Research Institute at Tennessee Oncology — Nashville
    • Tennessee Oncology — Nashville

  • Texas (6)

    • USOR Texas Oncology — Abilene
    • Texas Oncology – Central / South Texas — Austin
    • Mary Crowley Cancer Research — Dallas
    • USOR Texas Oncology — Fort Worth
    • Texas Oncology – Northeast TX — Tyler
    • USOR Texas Oncology Gulf Coast — Woodland

  • Utah (1)

    • START Mountain Region — West Valley City

  • Virginia (2)

    • USOR Virginia Cancer Specialists — Fairfax
    • USOR Virginia Oncology Associates — Norfolk

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT07563738

A 2-part Phase 1/2 Open-label Trial on ODM-212

An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

Locations

  • Texas (1)

    • NEXT Oncology — Irving

  • Virginia (1)

    • NEXT Oncology Virginia — Fairfax

NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Locations

  • Arizona (1)

    • Mayo Clinic — Phoenix

  • California (1)

    • UC San Diego Moores Cancer Center — La Jolla

  • Colorado (1)

    • Sarah Cannon Research Institute at HealthONE — Denver

  • Florida (1)

    • Mayo Clinic — Jacksonville

  • Illinois (1)

    • University of Chicago — Chicago

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • New York (1)

    • Memorial Sloan Kettering Cancer Center — New York

  • Ohio (1)

    • Cleveland Clinic — Cleveland

  • Oregon (1)

    • Oregon Health and Science University — Portland

  • Texas (3)

    • The University of Texas MD Anderson Cancer Center — Houston
    • NEXT Oncology Houston — Houston
    • NEXT Oncology Dallas — Irving

  • Virginia (1)

    • NEXT Oncology Virginia — Fairfax

Financial Support for Treatment in Virginia

Local financial aid programs can provide economic help at just the right time for patients receiving mesothelioma treatment in Virginia. Nonprofits like Daniel’s Grace and the MLC Cancer Foundation can cover medical and non-medical expenses, easing the burden that Virginia mesothelioma patients face. Examples range from free meal delivery and medical equipment programs to insurance copays and emergency grants.

Getting Financial Aid for Mesothelioma Support

  • Cancer Outreach Foundation: This Kingsport-Bristol area cancer nonprofit helps patients in Southwest Virginia cover the cost of medical supplies, transportation, prescriptions and other treatment-related expenses.
  • Daniel’s Grace Charitable Foundation: Located in Virginia Beach, Daniel’s Grace helps cancer patients facing economic struggles throughout the state. Families can get financial assistance with COBRA insurance premiums and living expenses, such as rent, mortgage payments, utilities, meals or groceries. The nonprofit deposits funds for approved expenses directly to service providers.
  • Danville-Pittsylvania Cancer Association: This community-supported nonprofit offers broad financial aid and support resources to mesothelioma patients in the region. Families can apply for up to $500 a month for help with household expenses, in addition to mileage reimbursements, nutritional supplements, prescription copays, $50 hotel vouchers and free medical equipment such as shower chairs, ramps and walkers.
  • Halifax County Cancer Association: Families facing a cancer diagnosis in Halifax County can apply for financial aid regardless of income or economic status. The HCCA provides gas cards for treatment-related travel, free wigs and chemotherapy accessories, and financial assistance with medications for cancer treatment, palliative care or symptom relief. The foundation also loans out available medical equipment like wheelchairs and hospital beds.
  • Hawthorne Cancer Foundation: Mesothelioma patients receiving treatment in the Tri-City and Richmond Metropolitan regions can apply for a Hawthorne Cancer Foundation grant. These grants can help with non-medical expenses, such as gas cards, rent, mortgage payments, car insurance and groceries. Patients need a referral from a hospital social worker or Patient Advocate, and families are limited to one grant a year.
  • Lee’s Friends: Lee’s Friends focuses on providing financial assistance and practical support to cancer patients in Chesapeake, Norfolk, Portsmouth and Virginia Beach. Mesothelioma patients can receive annual grants of up to $250 for urgent non-medical expenses, such as car and auto insurance payments, phone bills, rent and food. Separately, the nonprofit offers free transportation to and from local cancer care appointments.
  • MLC Cancer Foundation: MLC is one of the few Virginia nonprofits that offer to help with medical expenses like insurance copays, cancer medications, hospital bills, deductibles and home healthcare costs. This nonprofit is based in Martinsville, but it supports cancer patients throughout Virginia.

Our Patient Advocates and Veterans Department have extensive experience supporting mesothelioma patients in Virginia. When families facing a mesothelioma diagnosis experience financial hardships, our Patient Advocates can search for county-level, state or national programs that offer emergency assistance for medical or non-medical expenses. In the case of veterans with mesothelioma, our team is proud to help U.S. service members and their families navigate the application process for VA supports such as disability compensation and survivor benefits.

Cancer Resources in Virginia

County-specific and state cancer support programs are available to help mesothelioma patients physically, mentally and emotionally. Organizations like the Cancer Action Coalition of Virginia and VCS Cancer Foundation in Fairfax offer support networks, educational resources, cancer rehabilitation programs and classes to alleviate stress and pain.

Connecting With Virginia Cancer Support Programs

  • Cancer Action Coalition of Virginia: For more than 25 years, the CACV has worked with the Virginia Department of Health to coordinate cancer education in the state. Every year, the CACV creates a detailed database of local, state and national cancer support groups that Virginia families can access freely.
  • Cancer Retreat Centers: Located in Richmond, Cancer Research Centers and the Blanton House offer free wellness programs and support groups for cancer patients and caregivers living in and around Richmond County. Programs include brunches, art and music therapies, gentle movement classes, gardening and exercise activities. Families can also reserve overnight stays at Blue Spring Farm near the Little River for hiking, fishing, canoeing and relaxation.
  • Life with Cancer: Northern Virginia cancer patients receiving treatment at the Inova Schar Cancer Center in Fairfax can benefit from free acupuncture and massage therapy sessions at Life with Cancer locations in Alexandria, Fairfax and Leesburg. Free services open to all mesothelioma patients include in-person and online nutrition classes, psychotherapy support groups, fitness classes, music therapy, events for stress relief and bereavement counseling.
  • VCS Cancer Foundation: Mesothelioma patients and caregivers living in Fairfax and Arlington Counties can receive valuable mental and emotional support through the VCS Comfort and Companionship program. Local volunteers spend time listening and talking with cancer patients in a relaxing environment with snacks and beverages.

The Virginia 211 program also offers a wide range of support resources for mesothelioma patients throughout the state. Virginians who need help getting to appointments, preparing meals or caring for loved ones at home can dial 211 to find and connect with available local programs. Some counties offer free in-home senior care and caregiver support services.

What Survivors Say About Their Mesothelioma Treatment in Virginia

Our Patient Advocates have had the privilege of helping many mesothelioma patients and caregivers in Virginia. The experiences of local mesothelioma survivors and families who lost loved ones to cancer speak volumes about the state’s excellent medical care, specialists, support networks and aid programs available when seeking treatment for mesothelioma in Virginia, even with a Stage IV diagnosis.

Experience From a Mesothelioma Survivor

“If you had not been there to guide me each step of the way, I would have felt helpless and perhaps given up,” Carrie shared. “I felt a sense of comfort in your words and your understanding of what we were going through. Your desire to help made me believe you truly had my brother’s best interest at heart.”

Carrie D., Peritoneal Mesothelioma